Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:06 2024-07-16 EDT			5-day change	1st Jan Change
98.9 ^CHF	-0.20%		+1.86%	+16.53%

07-15	Brace for a flurry of speeches from Fed officials
07-15	European companies cut jobs as economy sputters	RE

Novartis AG Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

January 31, 2024 at 07:44 am

Novartis AG reported impairment charges for the fourth quarter ended December 31, 2023. For the quarter, the company reported property, plant and equipment impairment charges of USD 21 million compared to USD 91 million a year ago.

Latest news about Novartis AG

Brace for a flurry of speeches from Fed officials	07-15
European companies cut jobs as economy sputters	07-15	RE
MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger	07-15	MT
S&P 500 Rises Week-to-Week, Closes Near Highs Despite Mixed Inflation Data, Bank Earnings	07-12	MT
Novartis Seeks Squeeze Out Approval at MorphoSys AGM	07-12	MT
Global markets live: KKR, Apple, Tesla, Oracle, McDonald's...	07-12
Novartis to Close Technical Research Facility in San Diego, California; 100 Jobs Affected	07-11	MT
Novartis to Close Research Facility in San Diego, California; 100 Jobs Affected	07-11	MT
Markets Powered by Alternating Current	07-10
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	07-10	ZD
SIX to Cap SLI Index Weight of Nestle, Novartis Roche, UBS	07-10	MT
European companies cut jobs as economy sputters	07-09	RE
Lexicon Pharmaceuticals Names Mike Exton CEO, Jeff Wade Operating Chief	07-08	MT
Novo Nordisk Reprimanded in UK Over Undisclosed Payments; Novartis, Pfizer Found in Breach of Industry Code	07-05	MT
UK Pharmaceutical Trade Group Slams Novartis, Three Others for Breaches	07-05	MT
NOVARTIS AG : Berenberg sticks Neutral	07-03	ZD
Carisma Therapeutics Notifies Novartis Pharmaceuticals of Terminated Manufacturing, Supply Agreement	07-02	DJ
NOVARTIS AG : Receives a Buy rating from Jefferies	07-02	ZD
NOVARTIS AG : Deutsche Bank reiterates its Buy rating	07-02	ZD
Fitch Affirms Novartis Ratings on Leading Position in Innovative Pharmaceutical Sector	07-02	MT
Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments	07-01	MT
New semester, new state of mind	07-01
NOVARTIS AG : Gets a Buy rating from Goldman Sachs	07-01	ZD
Foreign banks target Switzerland after UBS takeover of Credit Suisse	06-24	RE
NOVARTIS AG : Barclays reaffirms its Sell rating	06-24	ZD

Chart Novartis AG

Duration

Period

More charts

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

2024-07-18 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 01:24 pm

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

110.8 USD

Average target price

112.7 USD

Spread / Average Target

+1.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+16.53%	226B
ELI LILLY AND COMPANY	+63.17%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-4.26%	359B
MERCK & CO., INC.	+17.66%	325B
ABBVIE INC.	+8.65%	297B
ROCHE HOLDING AG	+5.89%	234B
AMGEN INC.	+15.38%	177B
PFIZER, INC.	+1.88%	165B
SANOFI	+2.41%	126B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Novartis AG Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

EPS Revisions